The local literature lacks comprehensive information regarding the actual incidence of intrauterine growth restriction (IUGR) and oligohydramnios and currently available therapeutic options. Therefore, the current study was planned with the objective to evaluate the impact of enoxaparin therapy compared with standard management on neonatal outcomes in pregnancies complicated by intrauterine growth restriction (IUGR) with oligohydramnios.
The use of enoxaparin is not yet a standard practice in pregnancies with IUGR and oligohydramnios without overt maternal thrombophilia. Given the notable incidence of IUGR and oligohydramnios and the limited therapeutic options currently available, exploring the potential benefits of enoxaparin therapy against standard management is both clinically and socially relevant. By investigating whether enoxaparin can improve fetal outcomes in this high-risk group, the findings of this study would generate evidence that could inform future management protocols, reduce preventable perinatal morbidity and mortality, and ultimately improve neonatal survival and health in Pakistan.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
108
Patients will receive standard management plus enoxaparin 40 mg subcutaneously once daily until delivery
Patients will continue with standard management alone.
Combined Military Hospital
Quetta, Balochistan, Pakistan
Live birth
The frequency of live birth will be noted. Delivery of a baby with signs of life at birth, irrespective of gestational age will be considered as live birth.
Time frame: 12 weeks
Low Birth weight
Frequency of low birth weight will be noted. Neonatal birth weight \<2.5 kg will be documented as low birth weight.
Time frame: 12 weeks
Neonatal Intensive Care Unit Admission
The frequency of admission to the neonatal intensive care unit will be noted.
Time frame: 7 days
Perinatal Mortality
Perinatal mortality will be labeled "yes" if there is a stillbirth or neonatal death within the first 7 days of life.
Time frame: 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.